ANIXA Biosciences Inc

Anixa has treated the first patient in the fifth cohort of its Phase 1 study at Moffitt Cancer Center with 1×10^7 CAR‑positive cells/kg, the highest dose level tested to date. No dose‑limiting toxicities were observed at the previous dose level (3×10^6/kg). The Lira‑Cel therapy targets the follicle‑stimulating hormone receptor and has shown long‑term survival of up to more than two years in some patients. The stock recently rose 14.7% to $3.27, with a market capitalization of $111 million. » Más en de.investing.com

The Korean Intellectual Property Office granted Anixa the patent (No. 10-2960889) for its breast cancer vaccine technology, providing protection in South Korea until 2040. The technology, exclusively licensed from the Cleveland Clinic, aims at prevention and treatment by immunization against human α-Lactalbumin. A phase‑1 study met all primary endpoints, was safe, well tolerated and showed an immune response in 74% of participants. Anixa remains clinically unbalanced but has more liquid assets than debt; analysts see price targets of $7–14 versus the current level of about $2.79. » Más en de.investing.com

The Mexican Institute of Industrial Property has granted Anixa Biosciences a patent (No. 432748) covering key aspects of its breast cancer vaccine targeting α-lactalbumin, protecting the technology in Mexico until 2040. The vaccine, licensed exclusively from the Cleveland Clinic, met primary endpoints in a phase‑1 trial, showed good tolerability and elicited immune responses in 74% of participants; a phase‑2 study is being prepared. According to its balance sheet, Anixa has more cash than debt and strong short-term liquidity; analysts set price targets between $9 and $14 versus a current share price of $3.01. » Más en de.investing.com